Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C-albicans in human immunodeficiency virus-infected patients

被引:75
作者
Martins, MD [1 ]
Lozano-Chiu, M [1 ]
Rex, JH [1 ]
机构
[1] Univ Texas, Sch Med, Dept Internal Med,Div Infect Dis, Ctr Study Emerging & Reemerging Pathogens, Houston, TX USA
关键词
D O I
10.1086/515006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In order to determine the current prevalence and incidence of fluconazole-resistant oropharyngeal candidiasis among human immunodeficiency virus (HIV)-infected patients, we conducted a prospective observational study of a consecutive series of HPV-infected patients. Of 128 enrolled patients, 70 patients completed four quarterly follow-up visits over a period of 1 year. Over this period, declining rates of carriage of Candida albicans (from 61% to 39%; P = .008) and of oropharyngeal candidiasis (from 30% to 4%; P < .001) were documented. Il:rends toward reduction in the frequency of fluconazole-resistant isolates (MIC, greater than or equal to 64 mu g/mL) were also seen. During the survey period, the mean (median) number of antiretroviral agents used per patient rose from 0.5 (0) to 1.8 (2) (P < .001). Thus, rather than progression, we observed declining rates of oropharyngeal candidiasis, C. albicans carriage, and fluconazole-resistant C. albicans in a cohort of HIV-infected patients treated with increasingly effective antiretroviral therapy.
引用
收藏
页码:1291 / 1294
页数:4
相关论文
共 24 条
  • [1] Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1
  • [2] Protease inhibitors for HIV infection
    Bartlett, JG
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) : 1086 - 1088
  • [3] Reversible fluconazole resistance in Candida albicans: A potential in vitro model
    Calvet, HM
    Yeaman, MR
    Filler, SG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) : 535 - 539
  • [4] Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24): : 1962 - 1969
  • [5] Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
    Carr, A
    Cooper, DA
    [J]. LANCET, 1997, 349 (9057) : 995 - 996
  • [6] Candidiasis: The emergence of a novel species, Candida dubliniensis
    Coleman, DC
    Sullivan, DJ
    Bennett, DE
    Moran, GP
    Barry, HJ
    Shanley, DB
    [J]. AIDS, 1997, 11 (05) : 557 - 567
  • [7] HIV-1 protease inhibitors - A review for clinicians
    Deeks, SG
    Smith, M
    Holodniy, M
    Kahn, JO
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02): : 145 - 153
  • [8] CAN WE PREVENT AZOLE RESISTANCE IN FUNGI
    DENNING, DW
    [J]. LANCET, 1995, 346 (8973): : 454 - 455
  • [9] 2-5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy
    Elliot, B
    Aromin, I
    Gold, R
    Flanigan, T
    Mileno, M
    [J]. LANCET, 1997, 349 (9055) : 850 - 850
  • [10] Gazzard B, 1996, AIDS, V10, pS3